[go: up one dir, main page]

DK1567117T3 - Forebyggelse og behandling af mikrobe-medierede epitelsygdomme - Google Patents

Forebyggelse og behandling af mikrobe-medierede epitelsygdomme

Info

Publication number
DK1567117T3
DK1567117T3 DK02789898.0T DK02789898T DK1567117T3 DK 1567117 T3 DK1567117 T3 DK 1567117T3 DK 02789898 T DK02789898 T DK 02789898T DK 1567117 T3 DK1567117 T3 DK 1567117T3
Authority
DK
Denmark
Prior art keywords
methods
polyethylene glycol
gut
molecular weight
high molecular
Prior art date
Application number
DK02789898.0T
Other languages
English (en)
Inventor
John C M D Alverdy
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Application granted granted Critical
Publication of DK1567117T3 publication Critical patent/DK1567117T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pediatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DK02789898.0T 2002-11-26 2002-11-26 Forebyggelse og behandling af mikrobe-medierede epitelsygdomme DK1567117T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/037948 WO2004047778A1 (en) 2002-11-26 2002-11-26 Materials and methods for preventing and treating microbe-mediated epithelial disorders

Publications (1)

Publication Number Publication Date
DK1567117T3 true DK1567117T3 (da) 2012-05-21

Family

ID=32391449

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02789898.0T DK1567117T3 (da) 2002-11-26 2002-11-26 Forebyggelse og behandling af mikrobe-medierede epitelsygdomme

Country Status (13)

Country Link
US (3) US20060198817A1 (da)
EP (1) EP1567117B1 (da)
JP (1) JP5271475B2 (da)
KR (1) KR101087412B1 (da)
CN (1) CN100536836C (da)
AT (1) ATE544354T1 (da)
AU (1) AU2002352938B8 (da)
BR (1) BR0215954A (da)
CA (1) CA2507018C (da)
DK (1) DK1567117T3 (da)
ES (1) ES2381998T3 (da)
PT (1) PT1567117E (da)
WO (1) WO2004047778A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510004A (pt) * 2004-04-20 2007-09-18 Univ Chicago artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
GB2421908A (en) * 2004-12-23 2006-07-12 Univ College London Hospitals Medicament for treatment of inflammatory diseases
RU2365376C2 (ru) * 2005-05-23 2009-08-27 Владимир Александрович Малыгин Набор для лечения дисбактериоза и способ лечения
EP1906838A4 (en) * 2005-06-03 2008-10-08 Univ Chicago MODULATION OF MICROBIAL PATHOGENIC HOST CELL INTERACTIONS
WO2007101264A2 (en) * 2006-02-28 2007-09-07 The University Of Chicago Method for treating endothelial and epithelial cell disorders by administering high molecular weight peg-like compounds
GB0612748D0 (en) * 2006-06-27 2006-08-09 Univ College London Hospitals Treatment and/or prevention of inflammatory lung disease
WO2009036081A1 (en) * 2007-09-10 2009-03-19 University Of Kentucky Research Foundation Systems and methods for diagnosis and monitoring of bacteria-related conditions
JP5750096B2 (ja) * 2009-03-23 2015-07-15 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 放射線照射誘発型上皮障害を予防および治療する方法
WO2012040595A2 (en) 2010-09-23 2012-03-29 Inflammagen Administration of serine protease inhibitors to the stomach
WO2012092159A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
SG10202110501RA (en) 2010-12-31 2021-11-29 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
US20140057993A1 (en) * 2011-04-27 2014-02-27 Northshore University Healthsystem Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
BR112014001472A2 (pt) 2011-07-22 2017-02-21 Abbott Lab galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
BR112014004772A2 (pt) 2011-08-29 2017-03-21 Abbott Lab oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
WO2013038156A1 (en) * 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
CN103520202B (zh) * 2012-07-02 2015-09-02 舒泰神（北京）生物制药股份有限公司 用于通便和清肠的药物组合物
PT2968159T (pt) 2013-03-15 2019-10-01 Univ Michigan State Gestão de osteoporose com hmw peg
ITPD20130133A1 (it) * 2013-05-14 2014-11-15 Sanypet S P A Prodotto per l'alimentazione di cani affetti da disturbi infiammatori dell'intestino
CN106572987B (zh) 2014-03-25 2021-02-12 恒翼生物医药科技(上海)有限公司 用于治疗自身消化的组合物
CN110325175A (zh) * 2016-09-30 2019-10-11 芝加哥大学 具有病原体毒力抑制性能的磷酸化三嵌段共聚物
CN109637293B (zh) * 2019-02-16 2020-11-24 哈尔滨学院 一种用于蒲丰投针实验的数学概率演示装置
EP3791885A1 (en) * 2019-09-13 2021-03-17 Consejo Superior de Investigaciones Cientificas (CSIC) Polyethylene glycol for use in the prevention of abdominal inflammatory diseases and/or associated diseases
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487150A (en) * 1965-10-23 1969-12-30 Cornell Res Foundation Inc Dextran sulphate treatment of peptic ulcers
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4837008A (en) * 1985-04-09 1989-06-06 Peroxydent Group Periodontal composition and method
US4659572A (en) * 1985-04-15 1987-04-21 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Burn wound dressing material
USH1198H (en) * 1985-04-26 1993-06-01 Cetus Corporation Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5661177A (en) * 1988-11-09 1997-08-26 Chimie Et Biologie Zinc cysteate its preparation and uses in pharmacy and cosmetology
SE465109B (sv) 1989-10-30 1991-07-29 Bengt Andersson Antibakteriell komposition
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
US5350770A (en) 1992-07-28 1994-09-27 Elford Howard L Therapeutic process for the treatment of septic shock
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US6074671A (en) * 1993-10-01 2000-06-13 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception and prophylaxis against diseases transmittable by sexual contact and condom containing lectins
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6017334A (en) 1996-10-03 2000-01-25 Board Of Regents, The University Of Texas System Modified surfaces resistant to bacterial colonization
US6321909B1 (en) * 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
AU750136B2 (en) * 1997-06-03 2002-07-11 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
WO1999008514A1 (en) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions containing polyethylene glycol and uses thereof
EP1015445B1 (en) * 1997-09-15 2009-02-25 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
JP2002502826A (ja) * 1998-02-09 2002-01-29 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド Ｈｉｖ感染の治療用組成物および方法
EP1212086B8 (en) 1999-08-18 2008-01-02 Industry-Academic Cooperation Foundation, The Catholic University of Korea Immunological tolerance-induction agent
WO2001017560A1 (en) 1999-09-10 2001-03-15 Children's Medical Center Corporation Method for treating and preventing bacterial infection
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
CN1491676A (zh) * 2002-10-22 2004-04-28 刘小兵 经皮式(或口服式)避孕堕胎杀菌组合物

Also Published As

Publication number Publication date
CA2507018C (en) 2014-03-25
KR101087412B1 (ko) 2011-11-25
WO2004047778A1 (en) 2004-06-10
JP5271475B2 (ja) 2013-08-21
BR0215954A (pt) 2005-09-13
PT1567117E (pt) 2012-05-09
EP1567117A4 (en) 2009-07-08
AU2002352938B2 (en) 2009-09-10
EP1567117A1 (en) 2005-08-31
AU2002352938A1 (en) 2004-06-18
US9549946B2 (en) 2017-01-24
AU2002352938B8 (en) 2009-10-08
US20060198817A1 (en) 2006-09-07
ATE544354T1 (de) 2012-02-15
KR20050115855A (ko) 2005-12-08
EP1567117B1 (en) 2012-02-08
JP2006515837A (ja) 2006-06-08
US20160129038A1 (en) 2016-05-12
ES2381998T3 (es) 2012-06-04
US20170281668A1 (en) 2017-10-05
CN100536836C (zh) 2009-09-09
CA2507018A1 (en) 2004-06-10
HK1081445A1 (zh) 2006-05-19
CN1697644A (zh) 2005-11-16

Similar Documents

Publication Publication Date Title
DK1567117T3 (da) Forebyggelse og behandling af mikrobe-medierede epitelsygdomme
UA104634C2 (xx) Пегильована l-аспарагіназа $пегилированная l-аспарагиназа
PL1933869T3 (pl) Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
WO2007016525A3 (en) Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
UY27627A1 (es) Aza - arilpiperazinas
DK1543063T3 (da) Medikament levering
PH12019502782A1 (en) Fixed dose formulations
AR058866A1 (es) Un polimero biocompatible, no biodegradable, no toxico, util para composiciones farmaceuticas en nanoparticulas
WO2009037583A3 (en) Compositions and methods for treatment and prevention of osteoarthritis
EP2358395A4 (en) METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS
UY27204A1 (es) Derivados de pieracina
CO2022002998A2 (es) Derivado de heteroarilamidopiridinol y composición farmacéutica que comprende el mismo como ingrediente activo para prevención o tratamiento de enfermedad autoinmune
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2006073430A3 (en) Therapeutic delivery system comprising a high molecular weight peg-like compound
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
AR043253A1 (es) 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas
Paudel et al. Comparative evaluation of analgesic efficacy of tramadol and diclofenac-sodium in post-operative orthopedic patients
FI3870233T3 (fi) Paklitakseli-Hyaluronihapon konjugaatti käytettäväksi ei-lihasinvasiivisen virtsarakon syövän hoidossa
DE602004006024D1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
BR112012000410B8 (pt) uso de benzidamina ou dos sais de adição de ácido, e, composição farmacêutica